罗格列酮联合二甲双胍治疗2型糖尿病临床疗效  

The evaluation of therapeutic effect of Rosiglitazone combined with Metformin in the treatment of type 2 diabetes

作　　者：李海渝[1] 

机构地区：[1]北京航天总医院急诊科,北京100076

出　　处：《中国医药导报》2011年第23期76-77,共2页China Medical Herald

摘　　要：目的：探讨罗格列酮联合二甲双胍治疗2型糖尿病的临床疗效和安全性。方法：选取2008年1月～2010年1月我院诊断的2型糖尿病患者60例，给予罗格列酮和二甲双胍缓释片联合治疗。观察60例患者治疗前后空腹血糖（FBG）、餐后2h血糖、糖化血红蛋白（UbA1c）、总胆固醇（TC）、三酰甘油（TG）、胰岛素抵抗指数、胰岛素敏感指数变化，观察治疗过程中不良反应发生情况。结果：60例患者治疗后FBG、餐后2h血糖、HbA1c，TC、TG水平和胰岛素抵抗指数与治疗前比较均下降，差异有统计学意义（P〈0．05）。治疗后60例患者胰岛素敏感指数较治疗前升高，差异有统计学意义（P〈0．05）。60例患者治疗过程中发生低血糖4例，下肢水肿2例，胃肠道反应1例，不良反应发生率为11．7％。结论：罗格列酮联合二甲双胍治疗2型糖尿病可以有效的降低患者血糖水平，改善血脂代谢和胰岛素抵抗，不良反应较少。Objective： To explore the therapeutic effect of Rosiglitazone combined with Mefformin in the treatment of type 2 diabetes. Methods： 60 patients who were diagnosed type 2 diabetes were given Rosiglitazone combined with Mefformin therapy. FBG, 2 h BG, HbA1c, TC, TG, insulin resistance index, insulin sensitivity index before and after the treatment, ad- verse reaction conditions were observed. Results： 60 patients after treatment FBG, 2 h postprandial blood sugar, HbA1c, TC, TG level and insulin resistance index significantly decreased compared with before treatment （P〈0.05）. After the treat- ment insulin sensitivity index significantly increased compared with before treatment （P〈0.05）. 4 cases of patients had hypoglycemia, 2 cases of lower limb edema, 1 case of gastrointestinal reaction, adverse reaction rate was 11.7%. Conclusion： Rosiglitazone combined with Mefformin for type 2 diabetes patients can effectively reduce blood glucose levels, improve blood lipid metabolism and insulin resistance and adverse reaction is less.

关 键 词：2型糖尿病 二甲双胍 罗格列酮 胰岛素抵抗 

分 类 号：R587.1[医药卫生—内分泌]